Literature DB >> 17514622

TGF-beta1 in chronic allograft nephropathy following renal transplantation.

Shelley Harris1, Beatrice M Coupes, Stephen A Roberts, Ian S D Roberts, Colin D Short, Paul E C Brenchley.   

Abstract

BACKGROUND: Evidence from experimental models and clinical studies supports a major role for transforming growth factor-beta1 (TGF-beta1) in renal fibrosis. The aim of this study was to use repeated measurement of plasma TGF-beta1 as an indicator of persistent expression in a cohort of patients during the first 2 years post-renal transplantation and to correlate the findings with the development of chronic allograft nephropathy (CAN).
METHODS: Active plasma TGF-beta1 was quantified in 100 consecutive renal allograft recipients (samples/patient = 35.6 +/- 12.9) under standard clinical management for a mean of 23 months (range 3.4-45 months). All patients were followed up for a minimum of 5 years.
RESULTS: By 5 years, 23 patients had developed biopsy-proven CAN (CAN+), all of whom had been positive for plasma TGF-beta1. Demographic data were compared between patients who were CAN+ and CAN-negative (CAN-) and were not significantly different. TGF-beta1 exposure expressed as area under the curve / day (AUC/day) was correlated with the incidence of CAN. A Cox regression model was used to investigate the interrelationship of CAN, acute cellular rejection (ACR) and TGF-beta1 levels. ACR episodes were predictive of the development of CAN (log-rank test, p=0.003). After allowing for the effect of ACR (hazard ratio [HR]=3.6; 95% confidence ratio [95% CI], 1.5-8.7) between patients with and without ACR episodes, p=0.003), the independent effect of TGF-beta1 was confirmed (HR=1.7; 95% CI, 1.1-2.6; per quartile; p=0.008).
CONCLUSION: The results demonstrate that episodes of ACR are highly predictive of chronic damage in the graft. Cumulative exposure to TGF-beta1 is identified as an independent predictor of CAN in the first 2 years posttransplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17514622

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  16 in total

1.  Potentiating Renal Regeneration Using Mesenchymal Stem Cells.

Authors:  Lauren Brasile; Nicholas Henry; Giuseppe Orlando; Bart Stubenitsky
Journal:  Transplantation       Date:  2019-02       Impact factor: 4.939

Review 2.  Molecular pathways involved in loss of graft function in kidney transplant recipients.

Authors:  Valeria R Mas; Kellie J Archer; Mariano Scian; Daniel G Maluf
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

3.  HMGB1, TGF-β and NF-κB are associated with chronic allograft nephropathy.

Authors:  Shi-Qi Zhao; Zhen-Zhen Xue; Ling-Zhang Wang
Journal:  Exp Ther Med       Date:  2017-10-17       Impact factor: 2.447

4.  Cumulative exposure to gamma interferon-dependent chemokines CXCL9 and CXCL10 correlates with worse outcome after lung transplant.

Authors:  D C Neujahr; S D Perez; A Mohammed; O Ulukpo; E C Lawrence; F Fernandez; A Pickens; S D Force; M Song; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2011-12-07       Impact factor: 8.086

5.  Cumulative exposure to CD8+ granzyme Bhi T cells is associated with reduced lung function early after lung transplantation.

Authors:  A Mohammed; O Ulukpo; E C Lawrence; F Fernandez; A Pickens; A A Gal; S D Force; K C Easley; C P Larsen; A D Kirk; D C Neujahr
Journal:  Transplant Proc       Date:  2011-12       Impact factor: 1.066

6.  The role of sildenafil in the development of transplant arteriosclerosis in rat aortic grafts.

Authors:  Shuai Luo; Mei Yang; Hao Jin; Zi-Qiang Xu; Yi-Fu Li; Peng Xia; Yi-Rrong Yang; Bi-Cheng Chen; Yan Zhang
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 7.  The pathogenesis and treatment of chronic allograft nephropathy.

Authors:  Can Li; Chul Woo Yang
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

Review 8.  Late kidney allograft loss: what we know about it, and what we can do about it.

Authors:  Anthony M Jevnikar; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

9.  VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome.

Authors:  Ursula Thiem; Georg Heinze; Rudolf Segel; Thomas Perkmann; Franz Kainberger; Ferdinand Mühlbacher; Walter Hörl; Kyra Borchhardt
Journal:  Trials       Date:  2009-05-29       Impact factor: 2.279

Review 10.  Chronic allograft nephropathy.

Authors:  Jeffery T Fletcher; Brian J Nankivell; Stephen I Alexander
Journal:  Pediatr Nephrol       Date:  2008-06-27       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.